Susquehanna International Group
IBER.U

Susquehanna International Group’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Susquehanna International Group’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,899
Closed -$159K – 14087
2022
Q4 		$159K Sell
15,899
-1,800
-10% -$18K ﹤0.01% 10424
2022
Q3 		$175K Sell
17,699
-22,207
-56% -$220K ﹤0.01% 11035
2022
Q2 		$391K Buy
39,906
+10,539
+36% +$104K ﹤0.01% 8855
2022
Q1 		$288K Hold
29,367
– – ﹤0.01% 10374
2021
Q4 		$294K Hold
29,367
– – ﹤0.01% 10549
2021
Q3 		$294K Hold
29,367
– – ﹤0.01% 10650
2021
Q2 		$295K Hold
29,367
– – ﹤0.01% 10805
2021
Q1 		$290K Buy
+29,367
New +$294K ﹤0.01% 10678

Susquehanna International Group's IBER.U Position: Q1 2023 in Review

Susquehanna International Group sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 15,899 shares — an estimated $159K sold.

Susquehanna International Group first reported a position in IBER.U in Q1 2021 and held it in 8 quarters. The position peaked at $391K in Q2 2022. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • Susquehanna International Group reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 15,899 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $159K.
  • Susquehanna International Group first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 8 quarters.
  • Susquehanna International Group's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $391K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.